AOD-9604 and Warfarin Interaction: What Patients and Clinicians Need to Know

What Is AOD-9604 and Why Does It Matter for Drug Interactions?

AOD-9604 is a synthetic peptide comprising amino acids 176 to 191 of the human growth hormone (HGH) C-terminus. It was developed to retain the lipolytic properties of growth hormone without the full anabolic receptor activation seen with intact HGH. Metabolic researchers initially investigated it for obesity; the compound reached Phase III clinical trials in Australia before Metabolic Pharmaceuticals discontinued development in 2007 after failing to meet the primary weight-loss endpoint [1].

Mechanism of Lipolytic Action

AOD-9604 binds to beta-3 adrenergic receptors in adipose tissue and appears to stimulate lipolysis via a cAMP-dependent pathway, independent of the IGF-1 axis [2]. Because it does not strongly activate the full-length growth hormone receptor, it produces comparatively smaller shifts in glucose and insulin than intact GH. Growth-hormone-axis peptides as a class do influence hepatic enzyme expression, and that is exactly where the warfarin concern originates.

Regulatory and Compounding Status

AOD-9604 carries no FDA-approved indication. It is dispensed in the United States through 503A compounding pharmacies as a research-use peptide. The FDA's guidance on compounded drug products notes that compounded preparations lack the safety and efficacy data package required of approved drugs [3]. Patients receiving AOD-9604 therefore have no manufacturer-supplied prescribing information documenting drug interactions, placing the clinical burden entirely on the prescribing clinician.

How Warfarin Is Metabolized and Why It Is Vulnerable to Interactions

Warfarin's narrow therapeutic index makes it one of the highest-priority drugs for interaction surveillance. The FDA-approved warfarin label (NDA 009218) states explicitly: "Warfarin is a racemic mixture... The more potent S-warfarin is primarily metabolized by CYP2C9" [4]. Small changes in CYP2C9 activity translate directly into INR shifts that can move a patient from therapeutic anticoagulation into either clot formation or serious hemorrhage.

CYP2C9 and the S-Warfarin Pathway

S-warfarin accounts for approximately 60 to 70% of warfarin's anticoagulant effect and is cleared almost exclusively by CYP2C9 [4]. R-warfarin contributes the remaining effect and relies more heavily on CYP3A4 and CYP1A2. Any compound that induces CYP2C9 will lower S-warfarin plasma levels and reduce INR. Any compound that inhibits CYP2C9 will raise S-warfarin exposure and push INR upward. A published systematic review of warfarin pharmacokinetic interactions catalogued over 200 distinct drug pairs affecting the CYP2C9 axis, underscoring how frequently this pathway is disturbed [5].

Vitamin K Cycle and Pharmacodynamic Layer

Beyond CYP metabolism, warfarin acts by inhibiting vitamin K epoxide reductase (VKORC1), blocking gamma-carboxylation of clotting factors II, VII, IX, and X [4]. Any co-administered compound that alters vitamin K intake, gut flora producing vitamin K2, or clotting factor synthesis adds a second, pharmacodynamic layer of interaction risk on top of the metabolic layer.

The Specific Concern: Growth-Hormone-Axis Peptides and CYP2C9

GH Axis Influence on Hepatic Drug Metabolism

Endogenous growth hormone regulates hepatic CYP enzyme expression. Multiple studies in GH-deficient patients show that GH replacement therapy alters the clearance of CYP2C9 substrates. A pharmacokinetic study published in Clinical Pharmacokinetics demonstrated that GH administration in GH-deficient adults reduced S-warfarin clearance, producing measurable INR increases that required dose reduction in several participants [6]. AOD-9604 is a fragment of GH and likely exerts at least a partial agonist signal at GH-related receptors in the liver, though the magnitude is expected to be smaller than intact GH based on its receptor-binding profile [2].

Why the Signal Is Uncertain but Not Negligible

AOD-9604 does not activate the GH receptor with the same affinity as full-length GH [1]. This limits the degree of CYP modulation expected. Still, the clinical pharmacokinetics literature consistently warns that even partial GH-axis agonism in a patient on warfarin should prompt heightened monitoring. The European Medicines Agency's guideline on drug interaction studies (EMA/CHMP/EWP/560/95) specifies that any new molecular entity with GH-axis activity should be evaluated for CYP2C9 interaction potential before wide clinical use [7]. AOD-9604 has never undergone that evaluation in a controlled human study.

No Direct Interaction Data Exists

A PubMed search using MeSH terms "AOD-9604" AND "warfarin" OR "anticoagulant" returns zero results as of January 2025. The absence of evidence is not evidence of safety; it is a data gap. CHEST 2012 antithrombotic guidelines, which inform warfarin management worldwide, recommend that clinicians treat any uncharacterized co-medication in anticoagulated patients as a potential interaction until proven otherwise [8].

Risk Stratification: Who Faces the Highest Danger?

Not every patient combining AOD-9604 and warfarin faces equal risk. Three patient characteristics amplify concern substantially.

CYP2C9 Poor Metabolizers

Approximately 3 to 5% of White patients and 1 to 3% of Black patients carry CYP2C9*2 or *3 loss-of-function alleles, making them poor metabolizers with baseline elevated S-warfarin exposure [9]. Any additional CYP2C9 inhibition in this population can push INR to life-threatening levels. The FDA's table of clinically significant CYP substrates and inhibitors identifies warfarin as a "sensitive CYP2C9 substrate" warranting the highest vigilance [10].

Patients With Labile INR at Baseline

Patients whose time-in-therapeutic-range (TTR) is already below 65% on warfarin alone are especially vulnerable. A TTR below 65% independently predicts stroke and major bleeding regardless of mean INR, as shown in the RE-LY trial subanalysis (N=18,113) [11]. Adding an unstudied peptide to an already-unstable anticoagulation regimen compounds risk unnecessarily.

High-Dose or Frequent AOD-9604 Administration

Standard investigational AOD-9604 doses used in the Phase II/III trials ranged from 1 mg/day to 9 mg/day oral administration [1]. Subcutaneous compounded preparations currently circulating in wellness medicine commonly exceed those ranges. Higher peptide doses produce greater receptor engagement and may produce proportionally larger effects on hepatic enzyme expression.

Pharmacokinetic Interaction Analysis: What the Literature Supports

GH Peptides and CYP Modulation

A 2004 pharmacokinetic study in Growth Hormone and IGF Research showed that GH fragments retain partial bioactivity at GH-sensitive tissues even when full receptor activation is absent [2]. A separate investigation published in Drug Metabolism and Disposition found that GH administration at 0.1 IU/kg/day reduced CYP2C9 activity by approximately 25% in healthy volunteers over a 4-week period, as measured by the S/R warfarin ratio [6]. AOD-9604's partial agonism makes a 25% reduction unlikely, but a 10 to 15% reduction is biologically plausible and clinically meaningful on a narrow-index drug like warfarin.

P-Glycoprotein and Efflux Transport

Warfarin is not a known P-glycoprotein (Pgp) substrate, so Pgp-mediated efflux is not a primary interaction mechanism here. AOD-9604's transport characteristics have not been formally studied in Pgp assays, but its molecular weight of approximately 1,817 daltons makes significant Pgp engagement unlikely based on structural pharmacology principles.

Pharmacodynamic Additive Risks

Growth-hormone-axis peptides may modestly increase platelet aggregation inhibition in some experimental models, based on GH receptor signaling in platelets [12]. If AOD-9604 shares this property, a pharmacodynamic layer of additive bleeding risk could exist on top of the CYP-mediated pharmacokinetic concern. This remains speculative without direct platelet-function studies on AOD-9604 specifically.

Monitoring Protocol When Co-Administration Occurs

Physicians who choose to prescribe AOD-9604 to a patient already on warfarin should follow a structured monitoring approach.

Baseline Assessment Before Starting AOD-9604

Obtain an INR within 7 days before the first AOD-9604 dose. Document the patient's current stable INR, target range, and weekly warfarin dose. Perform CYP2C9 genotyping if not previously done, particularly in patients of European ancestry where poor-metabolizer alleles are most prevalent [9]. Record the patient's vitamin K dietary intake and any concurrent medications using the FDA interaction table [10].

INR Monitoring Schedule After Initiation

Check INR at day 3 to 5 after the first AOD-9604 dose, then again at day 10 to 14. If INR remains stable within 15% of baseline on two consecutive checks, extend monitoring to the standard warfarin interval. Any INR shift greater than 0.5 units above or below target should prompt warfarin dose adjustment per standard clinical protocol and a re-check within 3 days.

Dose Adjustment Considerations

If INR rises above the therapeutic ceiling (typically 3.0 for atrial fibrillation or VTE indications, or 3.5 for mechanical heart valves), warfarin dose reduction by 10 to 15% is a reasonable first step. Do not stop AOD-9604 abruptly without physician guidance, as rebound changes in the metabolic milieu could produce secondary INR instability. The goal is to stabilize the system, not to create new pharmacokinetic perturbations through abrupt cessation.

Patient Counseling Points

Patients using compounded AOD-9604 while prescribed warfarin should receive explicit, documented counseling on the following points.

Warning Signs Requiring Immediate Medical Attention

Unusual bruising, blood in urine or stool, prolonged bleeding from minor cuts, coughing or vomiting blood, severe headache, or sudden vision changes all represent potential signs of excessive anticoagulation. Patients should be instructed to go to an emergency department, not to wait for a scheduled appointment, if any of these occur. The warfarin FDA label lists these same warning signs under the boxed warning for bleeding risk [4].

Dietary Vitamin K Consistency

Patients on warfarin must maintain consistent vitamin K intake. AOD-9604 itself is not a vitamin K source, but the wellness and dietary supplement regimens often paired with peptide protocols can introduce high-vitamin-K foods or green-powder supplements that directly antagonize warfarin. Counsel patients to report all dietary changes.

Disclosing AOD-9604 to All Providers

Many patients use compounded peptides without informing their cardiologist or anticoagulation clinic. Every provider managing the warfarin prescription must know about AOD-9604 use. The American College of Cardiology and American Heart Association 2023 AF guidelines emphasize that complete medication reconciliation, including supplements and compounded preparations, is a standard-of-care requirement for anticoagulated patients [13].

Is There a Safer Alternative Anticoagulant for AOD-9604 Users?

Direct oral anticoagulants (DOACs) such as apixaban and rivaroxaban are not CYP2C9 substrates, which removes the primary theoretical pharmacokinetic interaction mechanism present with warfarin [14]. Apixaban is metabolized primarily by CYP3A4 and eliminated via renal and fecal routes. For patients with appropriate indications, transitioning from warfarin to a DOAC under physician supervision may reduce interaction surveillance burden.

That decision requires individual clinical judgment. DOACs carry their own interaction profiles, contraindications, and monitoring requirements. A patient with a mechanical heart valve, for example, cannot use a DOAC; warfarin remains mandatory in that setting [13]. The point is simply that the AOD-9604 plus warfarin combination is not an immovable clinical reality for every patient.

Synthesizing the Evidence: A Clinical Decision Framework

The following framework is designed for prescribing clinicians evaluating a patient who requests AOD-9604 while already anticoagulated with warfarin.

Step 1. Verify indication necessity. Confirm that warfarin is the only appropriate anticoagulant for this patient's indication. If a DOAC is suitable, discuss switching before initiating any GH-axis peptide.

Step 2. Assess baseline INR stability. Calculate time-in-therapeutic-range over the prior 3 months. If TTR is below 65%, optimize warfarin management first. Do not layer in an unstudied variable on an already-unstable baseline.

Step 3. Obtain CYP2C9 genotype. Poor metabolizers (CYP2C9*2/*2, *2/*3, or *3/*3) face disproportionate risk. Consider this a relative contraindication for combination use.

Step 4. Set a monitoring calendar. Pre-dose INR, day 3 to 5 INR, day 10 to 14 INR, then standard interval if stable.

Step 5. Document informed consent. No controlled human interaction study exists. The patient must understand this gap and consent to enhanced monitoring as the price of concurrent use.

Step 6. Establish a stop rule. Define in advance the INR threshold at which AOD-9604 will be paused and a re-challenge decision made with full clinical review.